We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
New therapies are required for high grade aggressive B cell lymphomas. We will establish new models of these diseases using primary B cells taken from tonsils/apheresis cones, and tumour cells taken from affected lymph nodes. Using primary normal B cells we will deliver oncogenes and study their cell signalling effects, providing an opportunity to examine the early steps in tumour development. Using cells isolated from primary tumour tissues we will explore how these tumours grow in immunodeficient mice and study the contribution of the tumour microenvironment to tumour establishment and progression. Finally, we will interrogate an existing archive of paraffinembedded lymphoma samples to determine the extent to which any changes we observe in vitro and in the animal models recapitulate human disease. We expect this Programme of research to not only provide a better understanding of B cell lymphoma development, but also to lead to new therapies and also better animal models for testing these therapies.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
We will exclude: 1) Patients less than 1 month old and 2) Patients less than 16 years old whose parents do not give consent and 3) Children who object, despite parental consent and 4) Adult patients who do not/or cannot give consent
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Birmingham and funded by Blood Cancer UK Research; THE CHILDREN'S CANCER AND LEUKAEMIA GROUP; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 30501
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
